Plasma levels of IL-1β, TNFα and their specific inhibitors in undialyzed chronic renal failure, CAPD and hemodialysis patients

Kidney International

Volumn 45, Issue 3, 1994, Pages 890-896

  Pereira, Brian J G ^b   Shapiro, Leland ^b   King, Andrew J ^b   Falagas, Matheos E ^b   Strom, James A ^b   Dinarello, Charles A ^a  

^a TUFTS MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ANTAGONIST; UNCLASSIFIED DRUG;

ARTICLE; BLOOD LEVEL; CHRONIC KIDNEY FAILURE; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CONTROLLED STUDY; HEMODIALYSIS; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

EID: 0028175027     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1038/ki.1994.117     Document Type: Article

References (56)

1. HENDERSON LW, KOCH KM, DINARELLO CA, SHALDON S: Hemodialysis hypotension: The interleukin hypothesis. Blood Purif 1:3-8, 1983
2. SHALDON S, DESCHODT G, BRANGER B, GRANOLLERAS C, BALDAMUS CA, KOCH KM, LYSAGHT MJ, DINARELLO CA: Hemodialysis hypotension: The interleukin hypothesis restated. Proc Eur Dial Transplant Assoc 22:229-243, 1985
3. SHALDON S, KOCH KM, DINARELLO CA: Interleukin-1 activation and acute phase response during hemodialysis. Contrib Nephrol 61:18-26, 1988
4. DINARELLO CA: Cytokines: Agents provocateurs in hemodialysis. (editorial review) Kidney Int 41:683-694, 1992
5. BINGEL L, LONNEMANN G, KOCH KM, DINARELLO CA, SHALDON S: Plasma interleukin-1 activity during hemodialysis: The influence of dialysis membranes. Nephron 50:273-276, 1988
6. DESCAMP-LATSCHA B, HERBELIN A, NGUYEN AT: Hemodialysis-membrane-induced phagocyte oxidative metabolism activation and interleukin-1 production. Life Supp Sys 4:349-353, 1986
7. HERBELIN A, NGUYEN, ZINGRAFF J, URENA P, DESCAMPS-LATSCHA B: Influence of uremia and hemodialysis on circulating interleukin-1 and tumor necrosis factor α. Kidney Int 37:116-125, 1990
8. HERBELIN A, URENA P, NGUYEN AT, ZINGRAFF J, DESCAMPS-LATSCHA B: Elevated circulating levels of interleukin-6 in patients with chronic renal failure. Kidney Int 39:954-960, 1991
9. LONNEMANN G, BINGEL M, KOCH KM, SHALDON S, DINARELLO CA: Plasma interleukin-1 activity in humans undergoing hemodialysis with regenerated cellulosic membranes. Lymphokine Res 6:63-70, 1987
10. LUGER A, KOVARIK J, STUMMVOLL HK, URBANSKA A, LUGER TA: Blood-membrane interaction in hemodialysis leads to increased cytokine production. Kidney Int 32:84-88, 1987
11. LONNEMANN G, VAN DEER MEER JWM, CANNON JG, DINARELLO CA, KOCH KM, GRANOLLERAS C, DESCHODT G, SHALDON S: Induction of tumor necrosis factor during extracorporeal blood purification. N Engl J Med 317:963-964, 1987
12. HOLMES C, EVANS R, ROSS D, FRANKAMP P: Plasma IL-1 and TNF levels during high flux hemodialysis with cellulose triacetate membranes. (abstract) Kidney Int 37:301, 1990
13. POWELL AC, BLAND L, OETTIGER CW, MAALLISTER S, OLIVER JC, ARDUINO M, FAVERO MS: Lack of elevation of plasma interleukin-1β or tumor necrosis factorα during unfavorable hemodialysis conditions. J Am Soc Nephrol 2:1007-1013, 1991
14. DAVENPORT A, CRABTREE J, ANDROJNA C, WILL EJ, DAVISON AM: Tumor necrosis factor does not increase during routine cuprophan hemodialysis in healthy well-nourished patients. Nephrol Dial Transplant 6:435-439, 1991
15. SECKINGER P, LOWENTHAL JW, WILLIAMSON K, DAYER J-M, MACDONALD HR: A urine inhibitor of interleukin 1 activity that blocks ligand binding. J Immunol 139:1546-1549, 1987
16. ENGELMANN H, ADERKA D, RUBINSTEIN M, ROTMAN D, WALLACH D: A tumor necrosis factor-binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity. J Biol Chem 264:11974-11980, 1989
17. OLSSON I, LANTZ M, NILSSON E, PEETRE C, THYSELL H, GRUBB A, ADOLF G: Isolation and characterization of a tumor necrosis factor binding protein from urine. Eur J Haematol 42:270-275, 1989
18. DINARELLO CA, ROSENWASSER LJ, WOLFF SM: Demonstration of a circulating suppressor factor of thymocyte proliferation during endotoxin fever in humans. J Immunol 127:2517-2519, 1981
19. SHALDON S, KOCH KM, BINGEL M, GRANOLLERAS C, DESCHODT G, DINARELLO CA: Modulation of plasma interleukin-1 and its circulating protein inhibitor (CPI) by hemodialysis and hemofiltration. (abstract) Kidney Int 31:245, 1987
20. EISENBERG SP, EVANS RJ, AREND WP, VERDERBER E, BREWER MT, HANNUM CH, THOMPSON RC: Primary structure and functional expression from complementary DNA of a human interleukin-1 receptor antagonist. Nature 343:341-346, 1990
21. PEREIRA BJG, POUTSIAKA DD, STROM JA, NARAYAN G, LEVEY AS, KING AJ, DINARELLO CA: In vitro production of interleukin-1 receptor antagonist in chronic renal failure, CAPD and HD. Kidney Int 42:1419-1424, 1992
22. SECKINGER P, ISAAZ S, DAYER JM: Purification and biologic characterization of a specific tumor necrosis factor alpha inhibitor. J Biol Chem 264:11966-11973, 1989
23. ENGELMANN H, NOVICK D, WALLACH D: Two tumor necrosis factor-binding proteins purified from human urine. Evidence for immunological cross-reactivity with cell surface tumor necrosis factor receptors. J Biol Chem 265:1531-1536, 1990
24. NOPHAR Y, KEMPER O, BRAKEBUSCH C, ENGELMANN H, ZWANG R, ADERKA D, HOLTMANN H, WALLACH D: Soluble forms of tumor necrosis factor receptors (TNF-Rs). The cDNA for the type I TNF-R, cloned using amino acid sequence data of its soluble form, encodes both the cell surface and a soluble form of the receptor. EMBO J 9:3269-3278, 1990
25. VAN ZEE KJ, KOHNO T, FISCHER E, ROCK CS, MOLDAWER LL, LOWRY SF: Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor-α in vitro and in vivo. Proc Natl Acad Sci USA 89:4845-4849, 1992
26. ADERKA D, ENGLEMANN H, HORNIK V, SKORNICK Y, LEVO Y, WALLACH D, KUSHTAI G: Increased serum levels of soluble receptors for tumor necrosis factor in cancer patients. Cancer Res 51:5602-5607, 1991
27. DIGEL W, PORSZOLT F, SCHMID M, HERRMANN F, LESSLAUER W, BROCKHAUS M: High levels of circulating soluble receptors for tumor necrosis factor in hairy cell leukemia and type B chronic lymphocytic leukemia. J Clin Invest 89:1690-1693, 1992
28. KALINOVICH A, ENGELMANN H, HARPAZ N, BURSTEIN R, BARAK V, KALICKMAN I, WALLACH D, BENTWICH Z: Elevated serum levels of tumor necrosis factor receptors (sTNF-R) in patients with HIV infection. Clin Exp Immunol 89:351-355, 1992
29. VAN DER MEER JWM, ENDRES S, LONNEMANN G, CANNON JG, IKEJAMA T, OKUSAWA S, GELFAND JA, DINARELLO CA: Concentrations of immunoreactive human tumor necrosis factor-α produced by human mononuclear cells in vitro. J Leukoc Biol 43:216-223, 1988
30. POUTSIAKA DD, CLARK BD, VANNIER E, DINARELLO CA: Production of interleukin-1 receptor antagonist and interleukin-1β by peripheral blood mononuclear cells is differentially regulated. Blood 78:1275-1281, 1991
31. SHAPIRO L, CLARK BD, ORENCOLE SF, POUTSIAKA DD, GRANOWITZ EV, DINARELLO CA: Detection of tumor necrosis factor soluble receptor p55 in blood samples from healthy and endotoxemic humans. J Infect Dis 167:1344-1350, 1993
32. CANNON JG, VAN DER MJW, KWIATKOWSKI D, ENDRES S, LONNEMANN G, BURKE JF, DINARELLO CA: Interleukin-1 beta in human plasma: optimization of blood collection, plasma extraction, and radioimmunoassay methods. Lymphokine Res 7:457-467, 1988
33. CANNON JG, NERAD JL, POUTSIAKA DD, DINARELLO CA: Measuring circulating cytokines. J Appl Physiol (in press)
34. MICHIE HR, MANOGUE KR, SPRIGGS DR, REVHAUG A, DWYER S, DINARELLO CA, CERAMI A, WOLFF SM, WILMORE DW: Detection of circulating tumor necrosis factor after endotoxin administration. N Engl J Med 318:1481-1486, 1988
35. CANNON JG, TOMPKINS RG, GELFAND JA, MICHIE HR, STANFORD GG, VAN DER MEER JWM, ENDRES S, LONNEMANN G, CORSETTI J, CHERNOW B, WILMORE DW, WOLFF SM, DINARELLO CA: Circulating interleukin-1 and tumor necrosis factor in septic shock and experimental endotoxin fever. J Infect Dis 161:79-84, 1990
36. CANNON JG, FRIEDBERG JS, GELFAND JA, TOMPKINS RG, BURKE JF, DINARELLO CA: Circulating interleukin-1β and tumor necrosis factor-α concentrations after burn injury in humans. Crit Care Med 20:1414-1419, 1992
37. KALECHMAN Y, GAFTER U, SRENDI B, LEVI J: Enhanced cytokine production by erythropoietin. (abstract) J Am Soc Nephrol 1:400, 1990
38. DINARELLO CA: Interleukin-1 and interleukin-1 antagonism. Blood 77:1627-1652, 1991
39. DINARELLO CA: ELISA kits based on monoclonal antibodies do not measure total IL-1β synthesis. J Immunol Meth 148:255-259, 1992
40. BROCKHAUS M, BAR-KHAYIM Y, GURWICZ S, FRENSDORFF A, HARAN N: Plasma tumor necrosis factor soluble receptors in chronic renal failure. Kidney Int 42:663-667, 1992
41. COTTRELL AC, MEHTA RL: Cytokine kinetics in septic ARF patients on continuous veno-veno hemodialysis (CVVHD). (abstract) J Am Soc Nephrol 3:361, 1992
42. ENDRES S, CANNON JG, GHORBANI R, DEMPSEY RA, SISSON SD, LONNEMANN G, VAN DER MEER JWM, WOLFF SM, DINARELLO CA: In vitro production of IL-1β, IL-1α, TNF and IL-2 in healthy subjects: Distribution, effect of cyclooxygenase inhibition and evidence of independent gene regulation. Eur J Immunol 19:2327-2333, 1989
43. GINSBERG H, MOLDAWER LL, SEHGAL PB, REDINGTON M, KILIAN PL, CHANOCK RM, PRINCE GA: A unique mouse model to investigate the molecular pathogenesis of adenovirus pneumonia. Proc Natl Acad Sci USA 88:1651-1655, 1991
44. SCHINDLER R, LINNENWEBER S, SCHULZE M, OPPERMANN M, DINARELLO CA, SHALDON S, KOCH KM: Gene expression of interleukin-1β during hemodialysis. Kidney Int 43:712-721, 1993
45. PEREIRA BJG, KING AJ, POUTSIAKA DD, STROM JA, DINARELLO CA: Comparison of first and reuse of cuprophan membranes on interleukin-1 receptor antagonist and interleukin-1β production by blood mononuclear cells. Am J Kidney Dis 22:288-295, 1993
46. AREND WP, WELGUS HG, THOMPSON RC, EISENBERG SP: Biological properties of recombinant human monocyte-derived interleukin-1 receptor antagonist. J Clin Invest 85:1694-1697, 1990
47. MCINTYRE KW, STEPAN GJ, KOLINSKY DK, BENJAMIN WR, PLOCINSKI JM, KAFFKA KL, CAMPEN RA, CHIZZONITE RA, KILIAN PL: Interleukin-1 receptor antagonist blocks acute inflammatory responses to IL-1 and other agents in vivo. J Exp Med 173:931-939, 1991
48. FISCHER E, MARANO MA, BARBER AE, HUDSON A, LEE K, ROCK CS, HAWES AS, THOMPSON RC, HAYES TV, ANDERSON TD, BENJAMIN WR, LOWRY SF, MOLDAWER LL: Comparison between effects of interleukin-1α administration and sublethal endotoxemia in primates. Am J Physiol 261:R442-R452, 1991
49. DINARELLO CA, THOMPSON RC: Blocking IL-1: Interleukin 1 receptor antagonist in vivo and in vitro. Immunol Today 12:404-410, 1991
50. FISCHER E, VAN ZEE KJ, MARANO MA, ROCK CS, KENNEY JS, POUTSIAKA DD, DINARELLO CA, LOWRY SF, MOLDAWER LL: Interleukin-1 receptor antagonist circulates in experimental inflammation and in human disease. Blood 79:2196-2200, 1992
51. LONNEMANN G, ENDRES S, VAN DER MEER JW, CANNON JG, KOCH KM, DINARELLO CA: Differences in the synthesis and kinetics of release of interleukin-1α, interleukin-1β and tumor necrosis factor from human mononuclear cells. Eur J Immunol 19:1531-1536, 1989
52. SPINAS GA, KELLER U, BROCKHAUS M: Release of soluble receptors for tumor necrosis factor (TNF) in relation to circulating TNF during experimental endotoxemia. J Clin Invest 90:533-536, 1992
53. PORTEU F, BROCKHAUS M, WALLACH D, ENGELMANN H, NATHAN CF: Human neutrophil elastase releases a ligand-binding fragment from the 75-kDa tumor necrosis factor (TNF) receptor. Comparison with the proteolytic activity responsible for shedding of TNF receptors from stimulated neutrophils. J Biol Chem 266:18846-18853, 1991
54. LESSLAUER W, TABUCHI H, GENTZ M, BROCKHAUS M, SCHLAEGER EJ, GRAU G, PIQUET H, POINTAIRE P, VASSALI P, LOETSCHER HR: Recombinant soluble TNF receptor proteins inhibit LPS-induced mortality in mice. (abstract) Cytokine 3:497, 1991
55. LANTZ M, THYSELL H, NILSSON E, OLSSON I: On the binding of tumor necrosis factor (TNF) to heparin and the release in vivo of the TNF-binding protein 1 by heparin. J Clin Invest 88:2026-2031, 1991
56. ADERKA D, ENGELMANN H, MAOR Y, CORD B, WALLACH D: Stabilization of the bioactivity of tumor necrosis factor (TNF) by its soluble receptors. J Exp Med 175:323-329, 1992